ATE395362T1 - Monoklonale antikörper zur apoptosis-induzierung - Google Patents

Monoklonale antikörper zur apoptosis-induzierung

Info

Publication number
ATE395362T1
ATE395362T1 AT98941848T AT98941848T ATE395362T1 AT E395362 T1 ATE395362 T1 AT E395362T1 AT 98941848 T AT98941848 T AT 98941848T AT 98941848 T AT98941848 T AT 98941848T AT E395362 T1 ATE395362 T1 AT E395362T1
Authority
AT
Austria
Prior art keywords
antibody
monoclonal antibodies
associated proteins
human integrin
apoptosis
Prior art date
Application number
AT98941848T
Other languages
English (en)
Inventor
Naoshi Fukushima
Shinsuke Uno
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ATE395362T1 publication Critical patent/ATE395362T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT98941848T 1997-09-11 1998-09-11 Monoklonale antikörper zur apoptosis-induzierung ATE395362T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP26485397 1997-09-11

Publications (1)

Publication Number Publication Date
ATE395362T1 true ATE395362T1 (de) 2008-05-15

Family

ID=17409137

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98941848T ATE395362T1 (de) 1997-09-11 1998-09-11 Monoklonale antikörper zur apoptosis-induzierung

Country Status (14)

Country Link
US (1) US20030157100A1 (de)
EP (1) EP1035132B1 (de)
KR (2) KR20010023866A (de)
CN (1) CN1198845C (de)
AT (1) ATE395362T1 (de)
AU (1) AU740225B2 (de)
CA (1) CA2303072A1 (de)
DE (1) DE69839492D1 (de)
HU (1) HUP0003513A3 (de)
NO (1) NO20001238L (de)
PL (1) PL339265A1 (de)
RU (1) RU2212413C2 (de)
SK (1) SK3232000A3 (de)
WO (1) WO1999012973A1 (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI960567L (fi) * 1993-09-03 1996-02-07 Chugai Pharmaceutical Co Ltd Monoklonaalinen vasta-aine, joka indusoi apoptoosin
US7531643B2 (en) * 1997-09-11 2009-05-12 Chugai Seiyaku Kabushiki Kaisha Monoclonal antibody inducing apoptosis
US7696325B2 (en) 1999-03-10 2010-04-13 Chugai Seiyaku Kabushiki Kaisha Polypeptide inducing apoptosis
EP1167388A4 (de) * 1999-03-10 2002-05-29 Chugai Pharmaceutical Co Ltd Apoptose induzierendes einzelsträngiges fv
TWI241345B (en) * 2000-03-10 2005-10-11 Chugai Pharmaceutical Co Ltd Apoptosis inducing polypeptide
US20040058393A1 (en) * 2000-04-17 2004-03-25 Naoshi Fukishima Agonist antibodies
WO2001079494A1 (fr) * 2000-04-17 2001-10-25 Chugai Seiyaku Kabushiki Kaisha Anticorps agonistes
RU2430927C2 (ru) * 2000-10-20 2011-10-10 Тугаи Сейяку Кабусики Кайся Агонистическое соединение, способное специфически узнавать и поперечно сшивать молекулу клеточной поверхности или внутриклеточную молекулу
WO2002033072A1 (fr) * 2000-10-20 2002-04-25 Chugai Seiyaku Kabushiki Kaisha Anticorps degrade, agoniste de tpo
US8034903B2 (en) 2000-10-20 2011-10-11 Chugai Seiyaku Kabushiki Kaisha Degraded TPO agonist antibody
US20040242847A1 (en) * 2000-10-20 2004-12-02 Naoshi Fukushima Degraded agonist antibody
EP1327681A4 (de) 2000-10-20 2004-09-01 Chugai Pharmaceutical Co Ltd Degradierte Agonisten Antikörper
EP2075256A2 (de) 2002-01-14 2009-07-01 William Herman Gezielte Liganden
AU2003271175A1 (en) 2002-10-11 2004-05-04 Masahiro Abe Cell death-inducing agent
JP2004279086A (ja) 2003-03-13 2004-10-07 Konica Minolta Holdings Inc 放射線画像変換パネル及び放射線画像変換パネルの製造方法
WO2004087763A1 (ja) * 2003-03-31 2004-10-14 Chugai Seiyaku Kabushiki Kaisha Cd22に対する改変抗体およびその利用
US8613922B2 (en) * 2003-04-24 2013-12-24 The University Of North Carolina At Chapel Hill Methods for inhibiting diabetic retinopathy with an antibody against integrin associated protein (IAP)
US8101719B2 (en) 2003-11-11 2012-01-24 Chugai Seiyaku Kabushiki Kaisha Humanized anti-CD47 antibody
JPWO2005056602A1 (ja) * 2003-12-12 2008-03-06 中外製薬株式会社 アゴニスト活性を有する改変抗体のスクリーニング方法
TW200530266A (en) * 2003-12-12 2005-09-16 Chugai Pharmaceutical Co Ltd Method of reinforcing antibody activity
KR20060130606A (ko) * 2003-12-12 2006-12-19 추가이 세이야쿠 가부시키가이샤 세포사 유도제
TW200530269A (en) 2003-12-12 2005-09-16 Chugai Pharmaceutical Co Ltd Anti-Mpl antibodies
EP1870458B1 (de) 2005-03-31 2018-05-09 Chugai Seiyaku Kabushiki Kaisha sc(Fv)2-STRUKTURISOMERE
WO2006123724A1 (ja) * 2005-05-18 2006-11-23 The University Of Tokushima 抗hla抗体を利用した新規医薬品
CN101262885B (zh) 2005-06-10 2015-04-01 中外制药株式会社 含有sc(Fv)2的药物组合物
CA2610987C (en) 2005-06-10 2013-09-10 Chugai Seiyaku Kabushiki Kaisha Stabilizer for protein preparation comprising meglumine and use thereof
US20070113297A1 (en) * 2005-09-13 2007-05-17 Yongguang Yang Methods and compositions for inhibition of immune responses
MX2009000487A (es) * 2006-07-13 2009-01-27 Chugai Pharmaceutical Co Ltd Inductor de muerte celular.
CL2008000719A1 (es) * 2007-03-12 2008-09-05 Univ Tokushima Chugai Seiyaku Agente terapeutico para cancer resistente a agentes quimioterapeuticos que comprende un anticuerpo que reconoce hla de clase i como ingrediente activo; composicion farmaceutica que comprende dicho anticuerpo; y metodo para tratar cancer resistente a
PL4160212T3 (pl) 2008-01-15 2024-08-12 The Board Of Trustees Of The Leland Stanford Junior University Markery komórek macierzystych ostrej białaczki szpikowej
FI3056514T4 (fi) 2008-01-15 2025-10-06 Univ Leland Stanford Junior Menetelmät cd47:n välittämän fagosytoosin manipuloimiseksi
AU2009279676C1 (en) 2008-08-07 2015-08-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Radioprotectants targeting thrombospondin-1 and CD47
KR102338833B1 (ko) * 2012-02-06 2021-12-13 인히브릭스, 인크. Cd47 항체 및 그 사용 방법
HK1216647A1 (zh) 2012-12-12 2016-11-25 Vasculox Inc. 治疗性cd47抗体
US9221908B2 (en) 2012-12-12 2015-12-29 Vasculox, Inc. Therapeutic CD47 antibodies
EP3349787A4 (de) 2015-09-18 2019-03-27 Arch Oncology, Inc. Therapeutische cd47-antikörper
JP2019522486A (ja) 2016-07-13 2019-08-15 プレジデント アンド フェローズ オブ ハーバード カレッジ 抗原提示細胞模倣足場およびそれを作製および使用するための方法
WO2018075960A1 (en) 2016-10-21 2018-04-26 Tioma Therapeutics, Inc. Therapeutic cd47 antibodies
KR20200091901A (ko) 2017-12-01 2020-07-31 시애틀 지네틱스, 인크. 암을 치료하기 위한 cd47 항체 및 이의 용도
CN110066336B (zh) * 2019-05-12 2021-11-09 杭州科兴生物科技有限公司 抗cd47单克隆抗体、片段及其医药用途
CN118829725A (zh) 2021-10-28 2024-10-22 莱尔免疫制药公司 生成细胞的方法
WO2024077174A1 (en) 2022-10-05 2024-04-11 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells
WO2025217398A1 (en) 2024-04-10 2025-10-16 Lyell Immunopharma, Inc. Methods for culturing cells with improved culture medium
WO2026006604A1 (en) 2024-06-26 2026-01-02 Lyell Immunopharma, Inc. Feeder cell replacement

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0672142T3 (da) * 1992-12-04 2001-06-18 Medical Res Council Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse
FI960567L (fi) * 1993-09-03 1996-02-07 Chugai Pharmaceutical Co Ltd Monoklonaalinen vasta-aine, joka indusoi apoptoosin
US6719972B1 (en) * 1994-06-03 2004-04-13 Repligen Corporation Methods of inhibiting T cell proliferation or IL-2 accumulation with CTLA4- specific antibodies
US5885574A (en) * 1994-07-26 1999-03-23 Amgen Inc. Antibodies which activate an erythropoietin receptor
US5783186A (en) * 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
EP0903149A4 (de) * 1996-03-06 2002-02-13 Chugai Pharmaceutical Co Ltd Verfahren zur bewertung von apoptosisverursachende substanzen
US7531643B2 (en) * 1997-09-11 2009-05-12 Chugai Seiyaku Kabushiki Kaisha Monoclonal antibody inducing apoptosis
US7696325B2 (en) * 1999-03-10 2010-04-13 Chugai Seiyaku Kabushiki Kaisha Polypeptide inducing apoptosis

Also Published As

Publication number Publication date
EP1035132B1 (de) 2008-05-14
AU740225B2 (en) 2001-11-01
SK3232000A3 (en) 2000-09-12
NO20001238D0 (no) 2000-03-09
KR20010023866A (ko) 2001-03-26
HUP0003513A3 (en) 2004-05-28
DE69839492D1 (de) 2008-06-26
EP1035132A1 (de) 2000-09-13
CN1198845C (zh) 2005-04-27
RU2212413C2 (ru) 2003-09-20
KR20040106585A (ko) 2004-12-17
US20030157100A1 (en) 2003-08-21
HUP0003513A2 (hu) 2001-02-28
CA2303072A1 (en) 1999-03-18
CN1276798A (zh) 2000-12-13
NO20001238L (no) 2000-05-11
WO1999012973A1 (en) 1999-03-18
EP1035132A4 (de) 2005-02-09
AU9002898A (en) 1999-03-29
PL339265A1 (en) 2000-12-04

Similar Documents

Publication Publication Date Title
DE69839492D1 (de) Monoklonale antikörper zur apoptosis-induzierung
ATE318147T1 (de) Spezifische monoklonale antikörperfür die extrazelluläre domäne von protasta-spezifischem membranantigen
EP1565489A4 (de) Neues raag10-zelloberflächenziel und dieses ziel erkennende antikörperfamilie
DE69635377D1 (de) Effiziente anreicherung und detektion von ausgesäten tumorzellen
DE69813158D1 (de) Assays zur Bestimmung von Proteinfragmenten in biologischen Medien
MX9603080A (es) Anticuerpos monoclonales inmuno-estimulantes.
ZA946767B (en) Monocional antibodies having property of causing apoptosis.
ATE395413T1 (de) Antikörperkategorisierung auf der grundlage von bindungseigenschaften
ATE123652T1 (de) Antigene.
DE69932812D1 (de) Epitope in der viralen hüllproteine und spezifische antikörper gegen diese epitope: verwendung für die detektion von hcv viralantigene im empfängergewebe
DK1167389T3 (da) Antistoffer mod SEMP1-proteinet, fremgangsmåde til fremstilling heraf samt anvendelse deraf
ATE202116T1 (de) Antikörperklassenspezifisches entstörungsreagenz
DE50009240D1 (de) Verwendung von Antikörpern zur Vakzinierung gegen Krebs
EA200200974A1 (ru) Моноклональные антитела к рецептору лпнп человека, их получение и применение
DK0812206T3 (da) Fremgangsmåde til stimulering af en immunrespons
ATE171473T1 (de) Humanisierte monoklonale antikörper gegen humanes interleukin - 4
ATE206621T1 (de) Il-8 antagonisten zur behandlung von asthma
DE69728897D1 (de) Saeugetierchemokine
DE69823660D1 (de) Methode zur identifizierung von tumorantigenen mit autoantikörpern in serum
ES2061324T3 (es) Complejo aglutinante como reactivo de identificacion de grupo sanguineo.
DE69132144D1 (de) Menschliche phospholipase aktivierender proteinteil
DE69533904D1 (de) Chemische Modifikation von Antikörpern und Antigenen
ATE137410T1 (de) Konjugate von ''pokeweed'' antiviralem protein und monoklonalen antikörpern
DE69716728D1 (de) Zytofluorometrisches verfahren zur bestimmung von antikörper gegen tumorantigene im serum

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties